Introduction {#Sec1}
============

As the world's population is increasing at an alarming rate, health problems have also become a very serious clinical problem. Therefore, it is an urgent requirement for the scientist to design and discover new drug molecules which possibly offers some of the greatest hopes for success in present and future epoch. However, there are still enormous numbers of pharmacologically active heterocyclic compounds which are in regular clinical use \[[@CR1]\]. Heterocyclic compounds are extensively distributed in nature and have versatile synthetic applicability and biological activity which helped the medicinal chemist to plan, organize and implement new approaches towards the discovery of novel drugs \[[@CR2]\].

Thiophene (Fig. [1](#Fig1){ref-type="fig"}) is a five membered heteroaromatic compound containing a sulfur atom at 1 position. It is considered to be a structural alert with formula C~4~H~4~S, chemical name is thiacyclopentadiene \[[@CR3]\].Fig. 1Thiophene

Thiophene was discovered as a contaminant in benzene \[[@CR4]\]. It has the molecular mass of 84.14 g/mol, density is 1.051 g/ml and Melting Point is − 38 °C. It is soluble in most organic solvents like alcohol and ether but insoluble in water. The "electron pairs" on sulfur are significantly delocalized in the π electron system and behaves extremely reactive like benzene derivative. Thiophene forms a azeotrope with ethanol like benzene. The similarity between the physicochemical properties of benzene and thiophene is remarkable. For example, the boiling point of benzene is 81.1 °C and that of thiophene is 84.4 °C (at 760 mmHg) and therefore, both are a well known example of bioisosterism \[[@CR5]\]. It can be easily sulfonated, nitrated, halogenated, acylated but cannot be alkylated and oxidized \[[@CR3]\].

In medicinal chemistry, thiophene derivatives are very important heterocycles exhibiting remarkable applications in different disciplines. In medicine, thiophene derivatives shows antimicrobial \[[@CR6]\], analgesic and anti-inflammatory \[[@CR7]\], antihypertensive \[[@CR8]\], and antitumor activity \[[@CR9]\] while they are also used as inhibitors of corrosion of metals \[[@CR10]\] or in the fabrication of light-emitting diodes in material science \[[@CR11]\].

Biological activities of thiophene derivatives {#Sec2}
----------------------------------------------

Thiophene nucleus containing compounds show various activities like for example 1-\[1-(2,5-dimethylthiophen-3-yl)ethyl\]-1-hydroxyurea (**1**) act as an anti-inflammatory agent; the maleate salt of 1-(2,5-dimethylthiophen-3-yl)-3-(5-methyl-1*H*-imidazol-4-yl)propan-1-one (**2**) work as serotonin antagonists and is used in the treatment of Alzheimer's disease.

2-Butylthiophene (**3**) is used as a raw material in the synthesis of anticancer agents and 2-octylthiophene (**4**) is used in the synthesis of anti-atherosclerotic agents such as (**5**). It also act as metal complexing agents and in the development of insecticides.

The higher alkylated thiophenes (**6**) has been used extensively as a raw material in patents relating to liquid crystals \[[@CR12]\].

Antimicrobial activity {#Sec3}
----------------------

Thiophene derivatives show high antimicrobial activity against various microbial infections. Different approaches were made to prove thiophene as antimicrobial agent by different scientist for the discovery of most active thiophene derivatives to the present scenario \[[@CR13]\].

Mehta et al. \[[@CR14]\] developed a new class of 4-(1-(3-chlorobenzo\[*b*\]thiophene-2-carbonyl)-1*H*-indol-3-yl)-7, 7-dimethyl-3,4,7,8-tetrahydroquinazoline 2,5(1*H*,6*H*)dione thiophene derivatives (Scheme [1](#Sch1){ref-type="fig"}). These synthesized compounds were screened for their antibacterial activity against three bacterial strains viz. *E. coli, P. aeruginosa, S. aureus* and three fungal strains viz. *C. albicans, A. niger, A. Clavatus* using serial broth dilution method. The standard drug used in this study was 'Ampicillin' for evaluating antibacterial activity which showed (50, 100, and 50 μg/ml) MIC against *E. coli, P. aeruginosa* and *S. aureus,* respectively. For antifungal activity 'Griseofulvin' was used as a standard drug, which showed (100, 100, and 100 μg/ml) MIC against *C. albicans, A. niger*, and *A. clavatus*, respectively. Among the synthesized derivatives, Compound **4** was found to be good active against *P. aeruginosa.* For the antifungal activity compounds **4** was considered as good active against *A. niger* and *A. clavatus.* The results of synthesized compounds presented in Table [1](#Tab1){ref-type="table"}.Scheme 1Synthesis of 4-(1-(3-chloro-6-fluoro-1-benzo\[*b*\]thiophene-2-carbonyl)-1*H*-indol-3-yl)-7,7-dimethyl-3,4,7,8-tetrahydroquinazoline 2,5(1*H*,6*H*)dione Table 1Biological activity of synthesized compoundsS. no.Antibacterial strainsAntifungal strainsGram negativeGram positive*E. coliP. aeruginosaS. AureusC. albicansA. nigerA. clavatus***4**500100250250100100SD10010050100100100Minimum inhibitory concentrations was expressed as (µg/ml)SD =  Ampicillin for antibacterial drug; SD = Griseofulvin for antifungal drug

Mazimba \[[@CR15]\] synthesized thiophene analogues of chalcones in good yields by condensation of 2-acetylthiophene and salicylaldehydes using Scheme [2](#Sch2){ref-type="fig"}. 1,5-Diketones were formed by solvent-free michael addition of cyclohexanone and 2-thienylchalcones devoid of hydroxyl groups which were used as synthons for synthesis of diazepines. The synthesized compounds were screened for in vitro antimicrobial activities against *S. aureus*, *E. coli*, *B. subtilis*, *P. Aeruginosa* and *C. Albicans* using dilution method. The compounds were found to show moderate to good antibacterial and antifungal activities. Among the tested compounds, diazepines (**7a**, **b**) exhibited excellent antibacterial (*S. aureus* and *P. aeruginosa*) and antifungal (*C. albicans*) activities. The results showed the importance of the carbon--nitrogen bond in biological systems because of which antimicrobial activities for these N-containing compounds were reported. The results of synthesized compounds showed in Table [2](#Tab2){ref-type="table"}.Scheme 2Synthesis of diazepines (**7a**, **7b**) Table 2Antimicrobial activity of thiophen-2-yl-chalcone derived heterocyclic compoundsS. no.*S. aureusE. coliB. subtilisP. aeruginosaC. albicans***7a**0.3130.6250.6250.3130.313**7b**0.3130.6250.6250.3130.313Ciprofloxacin0.6250.6250.6250.625--Fluconazole--------0.625Minimum inhibitory concentration (MIC; µg/ml)

Prasad et al. \[[@CR16]\] synthesized newly ethyl 2-amino-4-phenylthiophene-3-carboxylate derivatives using Scheme [3](#Sch3){ref-type="fig"}. The synthesized compounds were screened for their antibacterial activity by using minimum inhibitory concentration (MIC) method by taking ampicillin and streptomycin as standard drug. Among all the synthesized derivatives, compound **12** showed greater inhibitory effect against the organisms used, particularly against *B. subtilis*, *E. coli*, *P. vulgaris* and *S. aureus* with MIC. The present study has given deep insight as the 2-aminothiophene bearing 4-hydroxy benzaldehyde shown significant anti-microbial activity. The compound **12** showed the significant anti-microbial activity among all the synthesized 2-aminothiophene derivatives because of the presence of 4-hydroxy benzaldehyde at second position. The results of synthesized compounds presented in Table [3](#Tab3){ref-type="table"}.Scheme 3Synthesis of ethyl 2-(4-hydroxyphenylamino)-4-phenylthiophene-3-carboxylate Table 3Antimicrobial activity of 2-aminothiophene derivativesS. no.*P. vulgarisB. subtilisE. coliS. aureus***12**255012.550Ampicillin255012.550Streptomycin12.55012.525Minimum inhibitory concentration (µg/ml)

Lakshmi et al. \[[@CR17]\] synthesized 3-{\[(phenylhydrazono) (substituted phenyl)methyl\]diazenyl}-2-sulfanyl-2,3,5,6,7,8-hexahydro \[[@CR1]\] benzothieno\[2,3-*d*\]pyrimidin-4(1*H*)-one derivatives by using Scheme [4](#Sch4){ref-type="fig"}. All the synthesized compounds were screened for their antibacterial and antifungal activities against various microbes such as *B. subtilis*, *E. coli, P. aeruginosa* and *C. albicans* by the cup-plate agar diffusion method. From all the series, compounds **15a**, **15c**, **15g**, **15h**, **15i** were active against *B. subtilis*, compounds **15b**, **15d**, **15e**, **15h**, **15i** were active against *E. coli*, compounds **15a**, **15c**, **15d**, **15e**, **15g**, **15h**, **15i** showed activity against *P. aeruginosa* and compounds **15a**, **15b**, **15c**, **15f**, **15g**, **15h**, **15i** were found active against *C. albicans*. The results of synthesized compounds showed in Table [4](#Tab4){ref-type="table"}.Scheme 4Synthesis of 3-{\[(phenylhydrazono)(substitutedphenyl)methyl\]diazenyl}-2-sulfanyl-2,3,5,6,7,8-hexahydro \[[@CR1]\] benzothieno\[2,3-*d*\]pyrimidin-4(1*H*)-one (**15a**--**i**) Table 4Antimicrobial activity of benzothieno\[2,3-*c*\]chromen-6-one derivativesCompoundAntibacterialAntifungal*B. subtilisE. coliP. aureginosaC. albicans***15a**11001510**15b**00100014**15c**12001212**15d**00141300**15e**00101100**15f**00000012**15** **g**14001411**15** **h**12101213**15i**14111212Ampicillin151820--Fluconazole------15Minimum inhibitory concentrations was expressed as (µg/ml)

Havaldar et al. \[[@CR18]\] synthesized 10-methoxy-4,8-dinitro-6*H*-benzothieno\[2,3-*c*\]chromen-6-one derivatives by using Scheme [5](#Sch5){ref-type="fig"}. All the synthesized compounds were tested for their antibacterial activity against *S. aureus*, *E. coli*, *B. subtilis* and *S. typhosa* using concentrations of 2 and 5 µg/ml by the ditch plate technique. Among all the series, the compounds **20b** showed a much higher inhibitory effect on the growth of bacteria because of the presence of CH~3~ group. The results of synthesized compounds presented in Table [5](#Tab5){ref-type="table"}.Scheme 5Synthesis of 10-methoxy-4,8-dinitro-6*H*-benzothieno\[2,3-*c*\]chromen-6-one derivatives (**20a**--**c**) Table 5Antimicrobial activity of benzothienopyrimidinone derivativesCompd*S. aureusE. coliB. SubtilisS. typhosa*2 µg/ml5 µg/ml2 µg/ml5 µg/ml2 µg/ml5 µg/ml2 µg/ml5 µg/ml**20a**--++++--++++**20b**+++++++++**20c**--+++--+++Inhibition zone diameter: (--) \< 11 mm \[inactive\]; (+) 11--14 mm \[weakly active\]; (++) 15--18 mm \[moderately active\]

Ahmed et al. \[[@CR19]\] synthesized thieno\[3,2-*b*\]pyridine-2-one derivatives by using Scheme [6](#Sch6){ref-type="fig"}. The synthesized thienopyridines derivatives were evaluated for their in vitro antibacterial activity against two grampositive (*B. subtilis* and *S. aureus*) and two Gram-negative (*E. coli* and *S. typhi*) strains using paper disk diffusion assay method by comparing with amoxicillin (30 μg/disk) as reference antibiotic. The compounds **25a** and **25b** showed remarkable biological activity because of the substitution of the CN (at C3) either by acetyl (as in **25a**) and/or ethoxycarbonyl (as in **25b**). However, the antibacterial activity was slightly hampered by the existence of the electron withdrawing *p*-bromophenyl group at fourth position of carbon. The results of synthesized compounds presented in Table [6](#Tab6){ref-type="table"}.Scheme 6Synthesis of Ethyl 7-cyano-4-methyl-2-oxo-5-(phenylamino)-1,2-dihydrothieno\[3,2-*b*\]pyridine Table 6The in vitro antibacterial activity of the synthesized thienopyridines derivativesCompoundGram-positive speciesGram-negative species*B. SubtilisS. aureusE. coliS. typhosa***25a**12.512.52550**25b**6.312.52550Minimum Inhibitory Concentrations was expressed as (µg/ml)

Bhuiyan et al. \[[@CR20]\] synthesized a novel class of \[1,2,4\]triazolo\[4,3-*c*\]thieno-\[3,2-*e*\] pyrimidine derivatives using Scheme [7](#Sch7){ref-type="fig"} and assayed for the antibacterial activity against *B. cereus*, *S. dysenteriae* and *S. typhi* and for antifungal activity against *M. phaseolina*, *F. equiseti*, *A. alternate* and *C. corchori*. The disc diffusion method and poisoned-food techniques were used for antibacterial and antifungal activities, respectively. Among the synthesized compounds **28** and **33** resulted in wide spectrum antimicrobial activity against all the test bacteria and fungi using ampicillin and nystatin as a standard drug, respectively. Introduction of imidazo (**28**) or pyrazolo (**33**) moiety to the pyrimidine derivatives might be responsible for enhancement of antimicrobial activity of these compounds. The results of synthesized compounds are presented in Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}.Scheme 7Synthesis of thienopyrimidine derivatives Table 7Antibacterial activity of some synthesized compoundsCompoundZone of inhibition (mm)*B. cereusS. dysenteriaeS. typhi***28**201326**33**312829Ampicillin2130241 mg/ml per disc Table 8Antifungal activity of some synthesized compoundsCompoundInhibition of mycelial growth (%)^a^*M. phaseolinaF. equisetiA. alternateC. corchori***28**34.537.55450**33**48.365.665.454.5Nystatin71.844.751.640.5^a^1 mg/ml per disc

Khazi et al. \[[@CR21]\] developed some novel tricyclic thienopyrimidines and triazole fused tetracyclic thienopyrimidines derivatives by employing the Gewald reaction (Scheme [8](#Sch8){ref-type="fig"}). The synthesized compounds were evaluated against two Gram positive bacteria (*S. aureus*, *B. subtilis*), two Gram negative bacteria (*P. aeruginosa*, *E. coli*) and two yeast-like fungi *C. albicans* and *C. parapsilosis* using the broth micro dilution method. The result indicated that the compounds **35**, **37**, **39a**, **39b** and **39c** have exhibited good antibacterial activity against *B. subtilis* comparable to the standard ampicillin, while compound **38** displayed better antifungal activity against *C. albicans* comparable to the standard fluconazole. The results of synthesized compounds are presented in Table [9](#Tab9){ref-type="table"}.Scheme 8Synthesis of thienopyrimidines and triazolothienopyrimidines derivatives Table 9Antibacterial and antifungal activities of the compounds as MIC values (μg/ml)Compounds*S. aureusB. subtilisE. coliP. aeruginosaC. albicansC. parapsilosis***35**2561112825612864**37**51225625625616128**38**51211256256128256**39a**12811128256128128**39b**2561112825625664**39c**1281125612812864Ampicillin484------Fluconazole--------80.25

Tombary et al. \[[@CR22]\] synthesized series of tetrahydrobenzothieno\[2,3-*d*\]pyrimidine and tetrahydrobenzothienotriazolopyrimidine derivatives as presented in Scheme [9](#Sch9){ref-type="fig"} and evaluated for their antimicrobial activity using the cup diffusion technique against *S. aureus* as Gram-positive bacteria, *E. coli* and *P. aeruginosa* as Gram-negative bacteria in addition to *C. albicans* as fungi. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for the active compounds were studied and compared with ampicillin and clotrimazole as reference antibiotics. Antimicrobial testing revealed that compounds **44a** and **47** were the most active among the tested compounds against *C. albicans* while compounds **44b** and **46** showed the highest antibacterial potency against *P. aeruginosa* among the tested compounds. The significant results of these compounds are presented in Table [10](#Tab10){ref-type="table"}.Scheme 9Synthesis of tetrahydrobenzothieno\[2,3-*d*\]pyrimidine and tetrahydrobenzothienotri azolopyrimidine Table 10Antibacterial and antifungal activities of synthesized compoundsCompoundThe inhibition zones (IZ) in mm diameter*S. aureusE. coliP. aeruginosaC. albicans***44a**--151622**44b**--161916**46**21172020**47**--17--22Ampicillin252832--Clotrimazole------35(--) no inhibition zone, Minimum Inhibitory Concentrations was expressed as (µg/ml)

Adiwish et al. \[[@CR23]\] synthesized tetra substituted thiophenes from ketene dithioacetals as represented in Scheme [10](#Sch10){ref-type="fig"}. The synthesized compounds **49a** and **49b** were evaluated in vitro for their antibacterial activity against Gram-positive bacteria (*S. aureus* and *B. subtilis*) and Gram-negative bacteria (*E. coli* and *K. pneumonia*) by using agar disc-diffusion technique. The result revealed that compound **49a** exhibited bigger inhibition zones compared to **49b**. The results of synthesized compounds presented in Table [11](#Tab11){ref-type="table"}.Scheme 10Synthesis of tetrasubstituted thiophenes derivatives Table 11Antibacterial activities of newly synthesized compoundsBacteriaInhibition zones (mm)**49a49b**DMSOStreptomycin*B. subtilis*------25*S. aureus*97--13*E. coli*7----25*K. pneumonia*------25Minimum inhibitory concentrations was expressed as (µg/ml)

Reheim et al. \[[@CR24]\] synthesized some novel substituted thieno\[3,2-*c*\]pyrazole and pyrazolo\[3′,4′:4,5\]thieno\[2,3-*d*\]pyrimidine derivatives as represented in Scheme [11](#Sch11){ref-type="fig"}. The antimicrobial activity of the target synthesized compounds were screened against various microorganisms such as *E. coli*, *B. megaterium*, *B. subtilis*, *F. proliferatum*, *T. harzianum*, *A. niger* by the disc diffusion method. Antibacterial activity result indicated that among the synthesized derivatives, compounds **51**, **54** and **56** showed promising broad spectrum antibacterial activities against *E. coli*. The results of synthesized compounds presented in Table [12](#Tab12){ref-type="table"}.Scheme 11Synthesis of substituted thieno\[3,2-*c*\]pyrazole and pyrazolo\[3′,4′:4,5\]thieno\[2,3-*d*\]pyrimidine derivatives Table 12Antibacterial and antifungal activities of compound as MIC values (μg/ml)CompoundsBacterial speciesFungal species*E. coliB. megateriumB. subtilisF. proliferatumT. harzianumA. niger***54**151020121210**51**201220121512**56**151015201015Ampicillin232323------Clotrimazole------222222Inhibition zone diameter (mm)

Anticancer activity {#Sec4}
-------------------

Cancer is among the most challenging health problems worldwide which has become a major problem for increasing mortality rate globally. Currently available treatments such as chemotherapy and radiotherapy can only provide temporary therapeutic benefits as well as being limited by a narrow therapeutic index, remarkable toxicity, and acquired resistance for most of the type of cancer. However, the research of anticancer drugs in the past several decades has shown extensive progress and has cured considerable number of patients. Still it is the extreme area of investigation due to the complex physiological changes in the cell functionality, metastasis and apoptotic mechanisms. Lots of compounds were screened for anticancer activity in the past few years because of the presence of various cell lines and screening methods. Most of the scientist has synthesized and investigated some of novel thiophene derivatives for the anticancer activity carrying the biologically active sulfonamide, isoxazole, benzothiazole, quinoline and anthracene moieties \[[@CR25]--[@CR27]\].

Ghorab et al. \[[@CR28]\] developed a novel series of thiophenes derivatives having biologically active sulfonamide, isoxazole, benzothiazole, quinoline and anthracene moieties as presented in Scheme [12](#Sch12){ref-type="fig"}. The synthesized compounds were evaluated for in vitro anticancer activity against human breast cancer cell line (MCF7). Many of them showed cytotoxic activities compared to doxorubicin as a positive control. Among this series, (*Z*)-4-(3-oxo-3-(thiophen-2-yl)prop-1-enylamino)-*N*-(thiazol-2-yl)benzenesulfonamide (**59**), (*Z*)-4-(3-oxo-3-(thio-phen-2-yl)prop-1-enylamino)-*N*-(1-phenyl-1*H*-pyrazol-5-yl)benzenesulfonamide (**60**), (*Z*)-4-(3-oxo-3-(thiophen-2-yl)prop-1-enylamino)-*N*-(pyrimidin-2-yl)benzenesulfonamide (**61**) and (*Z*)-3-(4 methoxybenzo\[*d*\]thiazol-2-ylamino)-1-(thiophen-2-yl)prop-2-en-1-one (**62**) having IC~50~ values 10.25, 9.70, 9.55 and 9.39 μmol/l, respectively revealed a promising anti-breast cancer activity than that of doxorubicin with IC~50~ = 32.00 μmol/l. It was mainly due to the thiophene nucleus containing biologically active sulfathiazole **59**, sulfaphenazole **60**, sulfadiazine **61**, or benzothiazole **62** moieties. The results of synthesized compounds showed in Table [13](#Tab13){ref-type="table"}.Scheme 12Synthesis of thiophenes having the biologically active sulfonamide (**59**--**61**) and 3-methylisoxazole 12,4-methoxybenzo\[*d*\]thiazole (**62**) Table 13In vitro anticancer screening of the newly synthesized compounds against the human breast cancer cell line MCF7CompoundCompound concentration (μmol/l)Surviving fraction^a^102550100IC~50~ (μmol/l)Doxorubicin0.551 ± 0.0260.480 ± 0.0030.139 ± 0.0050.130 ± 0.01632.00**59**0.541 ± 0.0030.323 ± 0.0200.360 ± 0.0180.460 ± 0.01510.25**60**0.480 ± 0.0100.327 ± 0.0160.313 ± 0.0050.381 ± 0.0079.70**61**0.443 ± 0.0170.251 ± 0.0120.355 ± 0.0200.290 ± 0.0099.55**62**0.435 ± 0.0090.233 ± 0.0060.371 ± 0.0180.309 ± 0.0119.39^a^Mean ± S.E, *n *= 3

Gaunda et al. \[[@CR29]\] synthesized some new derivatives of 3-\[(2-substituted-6,7,8,9-tetrahydro-5*H*-cyclohepta\[*b*\]thieno\[2,3-*d*\]pyrimidin-4-yl)amino\]propan-1-ol derivatives (Scheme [13](#Sch13){ref-type="fig"}). The in vitro cytotoxicity activity of synthesized compounds were screened against both the cell lines (HC 29-Colorectal adenoma cell line and MDA 231-adenocarcinoma breast cancer cell line) by MTT assay and analyzed statistically. Among this series, the compound **69c** had shown better anticancer activity at all concentrations on both the cell lines followed by compound **69a**, **69b**. It was due to the phenyl substitution (**69c**) which has shown better anticancer activity. However, all the synthesized compounds showed considerable anticancer activity as compared to cyclophosphamide. The results of synthesized compounds presented in Table [14](#Tab14){ref-type="table"}.Scheme 13Synthesis of 3-\[(2-substituted-6,7,8,9-tetrahydro-5*H*-cyclohepta\[*b*\]thieno\[2,3-*d*\]pyrimidin-4-yl)amino\]propan-1-ol Table 14Anticancer activity of the title compounds (**69a**--**69c**)Compound codeConcentration (μmol)Percentage inhibition of cell growthHC 29-colorectal adenoma cell line (%)MDA 231-adenocarcinoma breast cancer cell line (%)**69a**0.0332.3931.180.0731.4329.350.1727.9624.47**69b**0.0330.7324.940.0727.9425.790.1725.2726.41**69c**0.0334.5233.680.0732.8330.720.1728.4525.35

Mohareb et al. \[[@CR30]\] developed a convenient synthetic approach for novel thiophene and benzothiophene derivatives (Scheme [14](#Sch14){ref-type="fig"}). The in vitro cytotoxicity was screened against three tumor cell lines--MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer) and SF-268 (CNS cancer) and a normal fibroblast human cell line (WI-38) compared to the anti-proliferative effects of the reference control doxorubicin. Among the series, ethyl-5-amino-3-(4-chlorostyryl)-4-cyanothiophene-2-carboxylate (**74**), ethyl 5-amino-4-\[(4-methoxyphenyl)carbamoyl\]-3-methylthiophene-2-carboxylate (**76b**) and ethyl 5-(3-ethoxy-3-oxopropanamido)-3-methyl-4-(phenylcarbamoyl)thiophene-2-carboxylate (**77**) were found to be the most active compounds against the three tumor cell lines such as MCF-7, NCI-H460 and SF-268 where as they showed low potency against the normal fibroblasts human cell line (WI-38). It was revealed that higher cytotoxicity activity of compound **74** was due to the presence of the chloro group, OCH~3~ group in compound **76b** and the presence of two ethoxy groups in compound **77**. Thus it has been shown that, in most cases, the electronegative Cl, OCH~3~ and OC~2~H~5~ hydrophobic groups in the thiophene derivatives might play a very important role in enhancing the cytotoxic effect. The results of synthesized compounds presented in Table [15](#Tab15){ref-type="table"}.Scheme 14**a** Synthesis of various derivatives of thiophene, **b** Synthesis of various benzothiophene derivatives Table 15Anticancer activity of the title compoundsCompoundIC~50~ (μmol/l)^a^MCF-7NCI-H460SF-268WI-38**74**0.03 ± 0.0070.02 ± 0.0080.01 ± 0.004\> 100**76b**0.01 ± 0.0060.03 ± 0.0020.06 ± 0.005\> 100**77**0.01 ± 0.0030.02 ± 0.0010.01 ± 0.00166.5 ± 12.7DSMO94.3 ± 6.496.4 ± 10.298.6 ± 12.2\> 100Doxorubicin0.0428 ± 0.00820.0940 ± 0.00870.0940 ± 0.0070\> 100^a^Drug concentration required to inhibit tumor cell proliferation by 50% after continuous exposure of 48 h; data are expressed as mean ± SEM of three independent experiments performed in duplicates

Sharkawy et al. \[[@CR31]\] synthesized a series of thiophene incorporating pyrazolone moieties via diazo coupling of diazonium salt of 3-substituted-2-amino-4,5,6,7-tetrahydrobenzo\[*b*\]thiophenes with 3-methyl-1*H*-pyrazol-5(4*H*)-one, 3-methyl-1-phenyl-1*H*-pyrazol-5(4*H*)-one or 3-amino-1*H*-pyrazol-5(4*H*)-one, respectively as represented in Scheme [15](#Sch15){ref-type="fig"}. Newly synthesized derivatives were tested for cytotoxicity against the well known established model ehrlich ascites carcinoma cells (EAC) in vitro. The results showed clearly that compounds **80a**--**c** exhibited high cytotoxic activity than 5-fluorouracil which may be due to the presence of amino group in position 3 of the pyrazol-5-one moiety. Further, the order of antitumor activity of this series of synthesized compounds follows **80c** \< **80b** \< **80a** which may be due to replacement of CONH~2~ by CN or COOC~2~H~5~ groups of benzothiophene ring in position 3. The results of synthesized compounds showed in Table [16](#Tab16){ref-type="table"}.Scheme 15Synthesis of substituted-4-{2-\[(or 3-phenyl-)4,5,6,7-tetrahydrobenzo\[*b*\]thiophen-2-yl\]hydrazono}-1*H*-pyrazol-5(4*H*)-one derivatives Table 16Antitumor activity of synthesized compoundsCompound no% Dead100 µg/ml (%)500 µg/ml (%)25 µg/ml (%)5-Fluorouracil97.36838.6**80a**10098.694**80b**98.48165**80c**98.17960The % dead refers to the % of the dead tumor cells

Seley et al. \[[@CR32]\] synthesized tricyclic thieno-separated purine analogues using Scheme [16](#Sch16){ref-type="fig"}. These synthesized derivatives were screened for their cytotoxic activity against HCT116 colorectal cancer cell lines. In this series, compound **83** showed potent cytotoxic activity against cancer cell lines. It was due to the coupling of compound **83** to a ribo-sugar to create the thieno-separated nucleosides may increase the growth inhibitory properties of these analogues. The results of synthesized compounds presented in Table [17](#Tab17){ref-type="table"}.Scheme 16Synthesis of 6-Aminoimidazo\[4′,5′:4,5\]thieno\[3,2-*d*\]pyrimidine Table 17Tricyclic compound-induced inhibition of HCT116 growthTime (h)Compd0.1 µM1 µM10 µM100 µM24**83**96.1 ± 3.8106.6 ± 4.8104.8 ± 3.882.0 ± 7.848**83**105.1 ± 3.398.3 ± 4.3105.0 ± 2.171.5 ± 3.8^b^72**83**101.3 ± 7.396.1 ± 6.693.8 ± 12.151.5 ± 10.7^a^HCT116 cells were treated and growth was assessed. Data represent the average (SEM as a % of control-treated (DMSO) cells (*n *= 3--5)^a^*p *\< 0.05^b^*p *\< 0.005 when compared to control-treated cells

Mohareb et al. \[[@CR33]\] synthesized novel heterocyclic compounds from 2-cyano-*N*-(3-cyano-4,5,6,7-tetrahydrobenzo\[*b*\]thiophen-2-yl)-acetamide as presented in Scheme [17](#Sch17){ref-type="fig"}. The tumor cell growth inhibition activities of the newly synthesized thiophene systems were assessed in vitro on three human tumor cell lines, namely, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and SF-268 (CNS cancer) after a continuous exposure of 48 h. The results were compared to the antiproliferative effects of the reference control doxorubicin. In this series, compounds **89**, **86**, **88**, **85**, and **87** showed significant activity on the three tumor cell lines tested. The results of synthesized compounds showed in Table [18](#Tab18){ref-type="table"}.Scheme 17Synthesis ofsubstituted-1-(3-cyano-4,5,6,7-tetrahydrobenzo\[*b*\]thiophen-2-yl) derivatives Table 18Antiproliferative activity GI50 (μM) of the synthesized compoundsCompoundGI50 (μM)^a^MCF-7NCI-H460SF-268**85**10.8 ± 0.616.5 ± 0.816.7 ± 1.6**86**2.5 ± 0.510.4 ± 0.68.0 ± 0.4**87**16.7 ± 1.610.8 ± 0.616.5 ± 0.8**88**11.8 ± 0.614.5 ± 0.816.7 ± 1.6**89**2.0 ± 0.48.3 ± 0.84.0 ± 0.8Doxorubicin0.0428 ± 0.00820.0940 ± 0.00870.0940 ± 0.0070^a^Drug concentration required to inhibit tumor cell proliferation by 50% after continuous exposure of 48 h. Doxorubicin was used as positive control

Antioxidant activities {#Sec5}
----------------------

Madhavi et al. \[[@CR34]\] developed a novel class of substituted 2-(2-cyanoacetamido)thiophenes by cyanoacetylation of substituted 2-aminothiophene by using an effective cyanoacetylating agent, 1-cyanoacetyl-3,5-dimethylpyrazole as presented in Scheme [18](#Sch18){ref-type="fig"}. All the synthesized compounds were evaluated for in vitro antioxidant activity by scavenging 1,1-diphenyl-2-picrylhydrazyl (DPPH) and nitric oxide free radicals at 100 μM concentration. Among these evaluated compounds, 2-(2-cyanoacetamido)-4,5-dimethylthiophene-3-carboxamide (Compound **92a**) was found to possess highest anti-oxidant activity in both models of free radical scavenging. However in case of assay with nitric oxide free radical scavenging, the highest activity was exhibited by 2-(2-cyanoacetamido)-4,5-dimethylthiophene-3-carboxamide (Compound **92a**, 56.9%) and 2-(2-cyanoacetamido)-4,5,6,7-tetrahydrobenzo\[*b*\]thiophene-3-carboxamide (Compound **92b**, 55.5%). The greater activity of these compounds were attributed due to the polar nature of carboxamide or nitrile group at 3rd position on thiophene ring. The results of synthesized compounds presented in Tables [19](#Tab19){ref-type="table"} and [20](#Tab20){ref-type="table"}.Scheme 18Synthesis of substituted 2-aminothiophene Table 19Reduction of DPPH by substituted 2-(2-cyanoacetamido) thiophenesCompoundR~1~, R~2~R~3~% Inhibition at 100 μM**92a**--CH~3~--CONH~2~52.4Ascorbic acid64.7 Table 20Effect of substituted 2-(2-cyanoacetamido)thiophenes on scavenging of nitric oxideCompoundR~1~, R~2~R~3~% Inhibition at 100 μM**92a**--CH~3~--CONH~2~56.9**92b**--(CH~2~)~4~----CONH~2~55.5

Anti-inflammatory activity {#Sec6}
--------------------------

Bahashwan et al. \[[@CR35]\] synthesized new series of fused triazolo- and tetrazolopyrimidine derivatives (Scheme [19](#Sch19){ref-type="fig"}) and their anti-inflammatory activity was evaluated. Newly synthesized thienopyrimidine derivatives were screened for anti-inflammatory activity (percent inhibition of edema obtained by the reference drug and tested compounds, respectively) in comparison to that of indomethacin. Among the series, compounds **94**, **95**, **96**, **97** and **98** possess strong anti-inflammatory activity. The high anti-inflammatory activity was mainly due to the presence of electron-donating moieties which increase the pharmacological activity. The order of anti-inflammatory properties with the substitution of electron--donating group in pyrimidine derivatives follows as: hydrazine \> methyl \> cyanomethyl \> tetrazine \> amide as exhibited in compounds **94** \> **98** \> **95** \> **96** \> **97**, respectively. The results of synthesized compounds presented in Table [21](#Tab21){ref-type="table"}.Scheme 19Synthesis of thienotriazolopyrimidine derivatives Table 21Anti-inflammatory activity of the synthesized compoundsCompoundsEdema inhibition (means ± E.M)^a,b^ (%)1 h2 h3 h**94**42.3 ± 1.149.2 ± 1.257.1 ± 1.4**95**37.2 ± 1.346.3 ± 1.554.4 ± 1.1**96**34.5 ± 1.235.1 ± 1.548.2 ± 1.2**97**31.2 ± 1.235.1 ± 1.540.2 ± 1.6**98**39.1 ± 1.548.4 ± 1.255.6 ± 1.1Indomethacin44.7 ± 1.252.4 ± 1.261.2 ± 1.3^a^Dose 5 mg/kg b.m (p.o.)^b^ n = 6

Ouf et al. \[[@CR36]\] synthesized hydrazones derivatives which shows significant anti-inflammatory activities as presented in Scheme [20](#Sch20){ref-type="fig"}. The synthesized compounds were screened against the standard drug flurbiprofen. Among the synthesized hydrazones, the substituted 4-methoxy- **100a**, 4-chloro- **100b** and 4-nitro-derivatives **100c** have anti-inflammatory activities higher than that of hydrazone with an unsubstituted benzaldehyde group against the standard drug flurbiprofen. Thus, the lipophilicity plays an important role for the potent anti-inflammatory activity. The results of synthesized compounds presented in Table [22](#Tab22){ref-type="table"}.Scheme 20Synthesis of 2-((Benzo\[*d*\] \[[@CR1], [@CR3]\] dioxol-5-yl)vinyl)-4,5-dimethylthieno\[2,3-*d*\]-pyrimidine-6-carbohydrazones derivatives Table 22Anti-inflammatory activity of some synthesized compounds (% reduction in edema induced by yeast)CompoundPost treatment 3 h = %Post treatment 6 h = %**100a**26.634.4**100b**17.230.0**100c**24.234.2

Hafez et al. \[[@CR37]\] synthesized some of the novel benzothino-pyrimidine derivatives (Scheme [21](#Sch21){ref-type="fig"}) which showed considerable potent anti-inflammatory activity. The anti-inflammatory activity of the newly synthesized compounds were evaluated by applying carrageenan-induced paw edema bioassay in rats using indomethacin as a reference standard. Compounds **105**, **106**, **107**, **108** and **109** caused significant decreases in paw edema after 2, 3, 4 h after drug administration. Thus, it can be concluded that spirobenzothienopyrimidine moiety, phenylpyrazolothinopyrimidine, morphonyl and piperazinylthinopyrimidine ring systems are important for anti-inflammatory activity. The results of synthesized compounds presented in Table [23](#Tab23){ref-type="table"}.Scheme 21Synthesis of phenylpyrazolothinopyrimidine, morphonyl and piperazinylthinopyrimidine derivatives Table 23Anti-inflammatory effect of synthesized compoundsCompd. no.Oedema volume1 h2 h3 h4 h**105**49.4 ± 7.171.8 ± 6.7^a^76.4 ± 4.8^a^82.2 ± 5.2**106**44.2 ± 5.159.6 ± 4.7^a^67.8 ± 3.3^a^81.9 ± 3.2**107**61.0 ± 6.666.6 ± 5.9^a^68.6 ± 7.0^a^72.4 ± 7.4**108**66.4 ± 7.578.2 ± 3.5^a^81.3 ± 3.387.1 ± 2.1**109**56.2 ± 9.965.1 ± 7.5^a^55.9 ± 10.6^a^54.7 ± 7.2^a^Indomethacin49.8 ± 5.342.9 ± 5.1^a^45.9 ± 4.6^a^46.9 ± 5.8^aa^p \< 0.05: Statistically significant from the control using one way ANOVA (Two-sided Dunnett as Post Hoc test)

Antiurease activity {#Sec7}
-------------------

Rasool et al. \[[@CR38]\] synthesized variety of novel 5-aryl thiophenes derivatives containing sulphonylacetamide (sulfacetamide) using Scheme [22](#Sch22){ref-type="fig"}. The synthesized compounds were screened for their anti-urease activities by taking thiourea as standard drug. Among all the synthesized derivatives, compound **112**, *N*-((5′-methyl-\[2,2′-bithiophen\]-5-yl)sulfonyl)acetamide, showed excellent urease inhibition activity at 40 µg/ml and 80 µg/ml concentrations where the percentage inhibition values were found to be 92.12 ± 0.21 and 94.66 ± 0.11, respectively with an IC~50~ value \~ 17.1 ± 0.15 µg/ml. It is further concluded that the urease inhibitory activity of compound might be due to the presence of the electronic and steric effects of functional groups. The results of synthesized compounds are presented in Table [24](#Tab24){ref-type="table"}.Scheme 22Synthesis of *N*-(5-(5-methylthiophen-2-yl)thiophen-2 ylsulfonyl)acetamide Table 24Urease inhibition studies of 5-arylthiophene-2-sulfonylacetamidesCompoundPercentage activity at 15 µg/mlPercentage activity at 40 µg/mlPercentage activity at 80 µg/mlIC~50~ µg/ml**112**42.44 ± 0.1192.12 ± 0.2194.66 ± 0.1117.1 ± 0.15Standard47.1 ± 0.3165 ± 0.01--23.3 ± 0.21Standard = Thiourea

Anticonvulsant activity {#Sec8}
-----------------------

Dashyan et al. \[[@CR39]\] synthesized 2,4-disubstituted pyr ano\[4′′,3′′:4′,5′\]pyrido\[3′,2′:4,5\]thieno\[3,2-*d*\]pyrimidines derivatives by using Scheme [23](#Sch23){ref-type="fig"}. The synthesized compounds were screened for the anticonvulsant activity of by taking the comparator drug, diazepam which was performed using male albino mice weighing 18--24 g (200 animals) and rats (Wistar) weighing 120--140 g (40 animals of both sexes).Scheme 23Synthesis of 2,4-Disubstituted pyrano\[4′,3′:4,5\]pyrido\[2,3-*b*\]thieno\[3,2-*d*\]pyrimidine derivatives

The anticonvulsant activity of the compounds was assessed by the prevention of clonic twitches and the clonic component of convulsions caused by subcutaneous administration of 90 mg/kg metrazol in mice. When studying anticonvulsant activity, it was found that the compounds (**114a**, **b**, **c**) and (**115a**, **b**, **c**, **d**, **e**) caused a marked protective anticonvulsive effect, which developed in mice starting with a dose of 25 mg/kg, while statistically calculated dose (ED~50~) ranged from 23 to 56 mg/kg (Table [25](#Tab25){ref-type="table"}).Table 25Activity against metrazol convulsions for the compounds (**114a**, **b**, **c**), (**115a**, **b**, **c**, **d**, **e**), and diazepamCompoundActivity against metrazol convulsions\* (ED50, mg/kg)**114a**56.0 (36.0--100.8)**114b**40.0 (23.5--68.0)**114c**23.0 (15.9--33.1)**115a**40.0 (23.5--68.0)**115b**56.0 (36.0--100.8)**115c**34.0 (25.3--45.7)**115d**40.0 (23.5--68.0)**115e**56.0 (36.0--100.8)Diazepam0.51 (0.39--0.69)\* Probability levels at *p *= 0.05 are indicated in brackets

Antithrombotic activity {#Sec9}
-----------------------

Jubair et al. \[[@CR40]\] synthesized novel series of 2-(bromomethyl)-5-aryl-thiophenes derivatives via Suzuki cross-coupling reactions of various aryl boronic acids with 2-bromo-5 (bromomethyl)thiophene as given in Scheme [24](#Sch24){ref-type="fig"}. The synthesized compounds were screened for their antithrombolytic activity. All the Compounds (100 μL) having concentration of 1 mg/ml were added to the micro-centrifuge tubes containing venous blood, and incubated at 37 °C for 45 min. Streptokinase was used as standard clot lysis agent and water as negative control for this assay. Among all the synthesized compounds, **118** showed potent clot lysis (31.5%). However, the results were significant p \< 0.05, when compared with streptokinase. Clot lysis activity results are presented in Table [26](#Tab26){ref-type="table"}.Scheme 24Synthesis of 2-(Bromomethyl)-5-(3,5-dimethylphenyl)thiophene Table 26Percentage efficiency of Clot lysis of synthetic compoundsCompoundsClot lysis %**118**31.5 ± 0.45Water0.43 ± 0.005Streptokinase87.2 ± 0.95The results are average ± S.D of triplicate experiments p \< 0.05

Conclusion {#Sec10}
==========

The analytical and other informational data, available in literature so far, have reveals that thiophene and its derivatives represent an important class of compounds in the medicinal field with various therapeutic potentials, i.e., antimalarial, antimicrobial, antimycobacterial, antidepressant, anticonvulsant, antiviral, anticancer, antihypertensive, anti-inflammatory and antioxidant. Appraisal of literature reports reveals that thiophene moiety have hiked a great deal of interests of medicinal chemist and biochemist to plan, organize and implement new approaches towards discovery of novel drugs.

This particular review article, established the fact that thiophene derivatives could be a rich source of potential entities in search of new generation of biologically active compounds and be worthwhile to explore the possibility in this area by fusing differently substituted moieties which may result in better pharmacological activities. Thus the quest to explore many more modifications on thiophene moiety needs to be continued.

PKV designed and finalized the scheme; RS performed review work and wrote the paper. Both authors read and approved the final manuscript.
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